Serum 13-14-diOH-15-keto-prostaglandin F2 alpha and airway response to meclofenamate and metaproterenol in relation to the menstrual cycle.
In order to evaluate whether adverse reactions to a nonsteroidal antiinflammatory agent (NSAIA) were related to variations in prostaglandin levels during the menstrual cycle, we measured 13-14-diOH-15-keto-prostaglandin F2 alpha in serum and the effect on airways of a single dose of 100 mg oral meclofenamate and 1.5 mg inhaled metaproterenol during the early (follicular phase) and late (luteal phase) menstrual cycle. Among 24 women with premenstrual asthma (PMA), four women with regular asthma (REA), and four healthy women, the 13-14-diOH-15-keto-PGF2 alpha averaged 140.9 +/- 68.4 pg/0.1 ml during the follicular phase but only 14.4 +/- 2.2 pg/0.1 ml during the luteal phase (p less than 0.0001). Acute asthma reactions to the meclofenamate occurred during the follicular phase in six women with PMA but were never observed during the luteal phase (p = 0.016). These reactions occurred preferentially in patients on corticosteroids (p = 0.004). Conversely, one patient with PMA had 18% improvement in FEV1 with meclofenamate during the luteal phase. A placebo-controlled, double-blind evaluation of the healthy women and the women with REA revealed a trend toward improvement in FEV1 during the luteal phase (0.15 less than p less than 0.10) but no change during the follicular phase. The effect of metaproterenol did not vary with the menstrual cycle, and there was no interaction between the effects of meclofenamate and those of metaproterenol. It appears that meclofenamate causes adverse effects on pulmonary function in asthmatic women primarily during the follicular phase of the menstrual cycle. This effect is associated with corticosteroid treatment and may be related to monthly variation in serum 13-14-diOH-15-keto-PGF2 alpha.
D000328:Adult; D001249:Asthma / Q000097:blood* / Q000139:chemically induced; D002986:Clinical Trials as Topic; D015237:Dinoprost / Q000031:analogs & derivatives*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008469:Meclofenamic Acid / Q000009:adverse effects*; D008597:Menstrual Cycle; D009921:Metaproterenol / Q000009:adverse effects*; D011293:Premenstrual Syndrome / Q000139:chemically induced; D000091402:Prohibitins; D011460:Prostaglandins F / Q000097:blood*; D012119:Respiration / Q000187:drug effects; D062367:ortho-Aminobenzoates / Q000009:adverse effects*
C000717331:PHB2 protein, human; D000091402:Prohibitins; D011460:Prostaglandins F; D062367:ortho-Aminobenzoates; D008469:Meclofenamic Acid; D009921:Metaproterenol; C051536:13,14-dihydroxy-15-ketoprostaglandin F2alpha; D015237:Dinoprost